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INTRODUCTION
Tramadol is an orally active drug that is widely used in the management of mild to moderately painful conditions in dogs (Gaynor, 2008; Lamont, 2008) . However, this use in dogs is controversial since clinical efficacy studies have produced conflicting results. Some studies indicate that tramadol is equally or more effective than other drugs used to treat pain in dogs (Mastrocinque and Fantoni, 2003; Almeida et al., 2010; Martins et al., 2010; Clark et al., 2011; Kukanich and Papich, 2011; Malek et al., 2012; Neves et al., 2012; Rialland et al., 2012; Kongara et al., 2013; Morgaz et al., 2013; Teixeira et al., 2013; Cardozo et al., 2014) , other studies have shown relatively poor analgesic efficacy in dogs (Davila et al., 2013; Delgado et al., 2014; Kogel et al., 2014) . Tramadol is considered a prodrug with regard to opioid analgesic effects, requiring metabolic activation by cytochrome P450 (CYP) enzymes. Consequently, variability in drug response between studies could be a consequence of genetic polymorphisms or drug-drug interactions involving the canine CYPs. However the CYPs responsible for metabolizing tramadol to its active metabolite in dogs are unknown.
In humans, tramadol is primarily metabolized in the liver to O-desmethyltramadol (M1) by CYP2D6 and to N-desmethyltramadol (M2) by CYP2B6 and CYP3A4 (Figure 1 ) (Subrahmanyam et al., 2001) .The analgesic effects of tramadol are primarily attributed to µ opioid-receptor activation by the M1 metabolite (KuKanich and Papich, 2004) , while both tramadol and M2 are essentially devoid of opioid agonist effects (Lai et al., 1996; Gillen et al., 2000) . The importance of CYP2D6-dependent metabolic activation of tramadol to M1 for analgesia has been demonstrated (in part) by studies of humans with CYP2D6 polymorphisms.
In one study, patients with the CYP2D6 poor metabolizer phenotype required higher tramadol doses and needed rescue pain medication more often than patients with the CYP2D6 extensive This article has not been copyedited and formatted. The final version may differ from this version. (Stamer et al., 2003) . Several other studies in human volunteers have also shown that the (opioid-dependent) miotic effects of tramadol and M1 plasma concentrations increase in proportion to CYP2D6 enzyme activity (Fliegert et al., 2005; Slanar et al., 2007; Matouskova et al., 2011) .
Tramadol and the M1 and M2 metabolites have two chiral centers in the cyclohexane ring (see Figure 1 ). All currently available pharmaceutical formulations of tramadol are a racemic mixture of (+)-(1R, 2R)-tramadol and (-)-(1S, 2S)-tramadol, also known as (+)-tramadol and (-)-tramadol, respectively. Interestingly, (+)-M1 appears to be a more effective µ opioid agonist than (-)-M1 (Raffa et al., 1993) . This was supported by a clinical study that showed about 2-fold lower (+)-tramadol and (+)-M1 plasma concentrations required for analgesia in human patients administered pure (+)-tramadol when compared with plasma concentrations of (-)-tramadol and (-)-M1 in patients who were administered pure (-)-tramadol (Grond et al., 1999) .
However, studies of tramadol metabolism by recombinant CYPs so far have used only racemic (±)-tramadol so it is unclear whether (+)-tramadol and (-)-tramadol are metabolized to their respective M1 and M2 metabolite stereoisomers by different CYPs or at different rates by specific CYPs (Subrahmanyam et al., 2001) . Dogs may differ in the capacity to metabolize tramadol to M1 when compared with other species. Specifically, pharmacokinetic studies have shown that average M1/tramadol area under the plasma concentration versus time curve (AUC) ratios after tramadol administration to dogs (0.027 to 0.1) (Giorgi et al., 2009; Kukanich and Papich, 2011) are quite low when compared with humans (0.27) (Garcia- and cats (1.4) (Cagnardi et al., 2011) suggesting that dogs may form M1 less efficiently than humans or cats.
Tramadol is also commonly used to treat pain in cats. In contrast to dogs, studies in cats This article has not been copyedited and formatted. The final version may differ from this version. (Pypendop et al., 2009; Evangelista et al., 2014) , which may be a consequence of the relatively high circulating M1 concentrations reported in cats after tramadol administration (Pypendop et al., 2009; Cagnardi et al., 2011) .
In this study we initially evaluated species differences in hepatic microsomal metabolism of racemic (±)-tramadol to M1 and M2 to test the hypothesis that M1 formation (relative to M2 formation) is slower in dog liver microsomes compared with cat and human liver microsomes.
We then used multiple approaches (recombinant enzymes, chemical and antibody inhibition, and induced hepatic microsomes) to identify the CYPs responsible for metabolizing (+)-tramadol and (-)-tramadol to M1 and M2 in dog liver. We had hypothesized that M1 would be formed by CYP2D15 (the canine ortholog of human CYP2D6), and that M2 would be formed by CYP2B11 and CYP3A12 (the canine orthologs of human CYP2B6 and CYP3A4).
This article has not been copyedited and formatted. The final version may differ from this version. Bactosomes expressing recombinant canine CYPs (1A1, 1A2, 2B11, 2C21, 2C41, 2D15, 3A12, and 3A26; each co-expressed with canine P450 oxidoreductase) and liver microsomes from male beagle dogs treated with corn oil, rifampin, β -naphthoflavone, saline, phenobarbital and clofibric acid were obtained from Xenotech LLC (Lenexa, KS). Liver microsomes were prepared as previously described (Court et al., 1997 ) from a bank of frozen dog livers maintained at Washington State University. Livers were from 27 untreated adult dogs including 5 Beagles (all males), 5 Greyhounds (all males), 12 mixed breed dogs (6 females and 6 males), 4
Chihuahuas (3 males and 1 female), and one Labrador retriever (male). All dogs were healthy and were being euthanized for reasons unrelated to the present study. Liver microsomes were prepared from a bank of frozen cat livers maintained at Washington State University that were obtained from 16 domestic short-haired cats (11 males and 5 females). The microsomal protein content of the human, dog, and cat liver microsomes used in this study were measured using the bicinchoninic acid assay (Thermo Scientific Pierce, Rockford, Illinois).
Tramadol metabolism assay using liver microsomes and recombinant CYPs. was assumed based on evidence from at least one study that showed the pure (+)-and (-)-enantiomers of tramadol and O-desmethyltramadol do not racemize (Grond et al., 1999) .
Inhibition assays
Chloramphenicol and quinidine were evaluated as inhibitors of M1 and M2 formation in minutes. The reaction was stopped by adding internal standard and the metabolites formed were measured by HPLC as described above.
An antibody inhibition assay was performed using rabbit anti-CYP2B11 immune serum that was a gift from Dr James Halpert, School of Pharmacy, University of Connecticut, Storrs, Connecticut (Duignan et al., 1987) . Pooled DLMs (0.2 mg/ml final concentration) were pre- For all inhibition assays, samples were prepared in triplicate, M1 and M2 formation rates were averaged, and then expressed as a percentage of control incubations that lacked inhibitor.
Enzyme kinetic and statistical analyses
Kinetic and statistical analyses were performed using Sigmaplot 12 software (Systat, San
Jose, CA). For enzyme kinetic analysis, enzyme kinetics parameters (Km and Vmax) were determined using either the one enzyme or the two enzyme Michaelis-Menten model using nonlinear regression analysis. The model of best fit was evaluated based upon plots of fitted versus observed data. Half-maximal inhibitory concentration (IC50) values were determined using nonlinear regression with a four parameter logistic curve. Differences in enzyme activities were evaluated using unpaired Student's t-test (two groups) or ANOVA (three groups) with post-hoc This article has not been copyedited and formatted. The final version may differ from this version. 
RESULTS
Racemic (±)-tramadol metabolism by dog, human and cat liver microsomes
Racemic (±)-tramadol was incubated at 5 µM substrate concentration with pooled liver microsomes from dogs (n = 27), humans (n = 48) and cats (n = 16) to evaluate species differences in tramadol metabolism. This substrate concentration was chosen since it roughly approximated maximal plasma concentrations (range 0.3 to 8 µM) observed in pharmacokinetic studies of tramadol in dogs administered at clinically used dosages (KuKanich and Papich, 2004; Giorgi et al., 2009; Kukanich and Papich, 2011) . Mean (± SD) M1 and M2 formation rates and M1 to M2 formation ratios for each substrate are shown in Fig. 2 . DLMs showed 3.9-fold lower M1 formation rates than cat liver microsomes (ANOVA with Tukey's test, P<0.001), but over 7-fold higher activities than human liver microsomes (P<0.001) (Fig. 2a) . On the other hand ( Fig. 5b and Fig. 5d ). However, at the lower concentration tested (5 µM), CYP2B11
was the most active enzyme for both (+)-tramadol and (-)-tramadol.
Enzyme kinetic analysis was then performed using the recombinant CYPs that showed the highest formation rates of M1 (CYP2D15), and M2 (CYP2B11, CYP2D15, CYP2C41, This article has not been copyedited and formatted. The final version may differ from this version. Fig. 6a and Fig. 6b , while plots of M2 formation from both (+)-tramadol and (-)-tramadol by CYP2B11 are shown in Fig. 6c and Fig. 6d . Derived enzyme kinetic parameters from all CYPs evaluated are given in Table 2 . Eadie-Hofstee plots showed monophasic kinetics for most activities evaluated. Exceptions that were best described by we then compared high and low affinity intrinsic clearance estimates for M1 formation by CYP2D15 for each enantiomer. Interestingly a similar pattern to that observed for DLMs was seen with CYP2D15 in that the M1 formation intrinsic clearance estimate for the high affinity activity was 4.6-times higher for (+)-tramadol compared with (-)-tramadol while the low affinity activity intrinsic clearance estimate was 1.5-times higher for (+)-tramadol compared with (-)-tramadol (Table 2) .
This article has not been copyedited and formatted. The final version may differ from this version. 
Relative contribution of CYPs to M1 and M2 formation
The relative contributions of each canine CYP to total formation of M1 and M2 in liver were then calculated using the measured intrinsic clearance estimates from Table 2 and normalized to hepatic CYP content using average published estimates (Heikkinen et al., 2015) that were available for CYP2B11 (35 pmol/mg protein), CYP2C21 (70 pmol/mg protein), CYP2D15 (56 pmol/mg protein) and CYP3A12 (93 pmol/mg protein) in Beagle liver microsomes. Unfortunately, an estimate of CYP2C41 hepatic abundance was not available. As shown in Fig. 7 , M1 was predominantly formed by CYP2D15 from both (+)-tramadol (99%) and (-)-tramadol (99%) with essentially no contribution from any other CYP evaluated (<1%).
Conversely, M2 was formed from (+)-tramadol and (-)-tramadol primarily by CYP2B11 (20%
and 50%) and CYP3A12 (68% and 32%), with smaller contributions from CYP2C21 (10% and 14%), and negligible contributions from CYP2D15 (1% and 4%).
Effect of CYP selective chemical and antiserum inhibitors
The effects of selective inhibitors of CYP2D15 (quinidine (Roussel et al., 1998) The effect of preincubation with increasing amounts of an inhibitory antiserum specific to CYP2B11 on M1 and M2 formation from (+)-tramadol and (-)-tramadol was evaluated using pooled DLMs. As shown in Fig. 9 there was selective inhibition (>50% decrease in mean activity from control) of M2 formation from (+)-tramadol and (-)-tramadol, without substantially affecting M1 formation from (+)-tramadol and (-)-tramadol at all CYP2B11 antiserum concentrations evaluated (5:1 to 20:1 antiserum to microsomal protein ratios).
Effect of CYP selective inducers
The impact of CYP selective inducers including β -naphthoflavone (CYP1A), phenobarbital (CYP2B), rifampin (CYP3A), and clofibric acid (CYP4A) on tramadol metabolism was evaluated using pooled liver microsomes from male Beagle dogs (2 per treatment) that had been administered each of these inducers. Results were compared to vehicle treated liver microsomes. Vehicles included corn oil for rifampin and ß-naphthoflavone, and saline for phenobarbital and clofibric acid. As shown in Fig. 10 
DISCUSSION
The major novel finding of this study is that tramadol is metabolized in dog liver to M1 by CYP2D15, while M2 is formed by multiple enzymes, primarily CYP2B11 and CYP3A12.
Multiple observations provide evidence supporting these conclusions, including recombinant enzyme activities, selective inhibition of M1 formation by quinidine, and of M2 formation by chloramphenicol and CYP2B11 antiserum, and induction of M2 formation (but not M1 formation) by phenobarbital. Recombinant enzyme activities also indicated minor contributions to M2 formation from CYP2C21 and CYP2D15 that account for less than 14% of liver activity when adjusted for published canine hepatic abundance of these CYPs (Heikkinen et al., 2015) .
Recombinant CYP2C41 also showed significant M2 formation activity especially from (+)-tramadol. Unfortunately, the hepatic protein abundance of CYP2C41 has not been reported and so the relative contribution of this enzyme to M2 formation in dog liver cannot be estimated at present. Although relatively little is known about CYP2C41, one study showed that only 4 of 25 dogs tested had the CYP2C41 gene possibly resulting from a gene deletion polymorphism (Blaisdell et al., 1998) . Consequently, one approach to evaluate the potential role of CYP2C41 in tramadol metabolism in dogs could involve comparing M2 formation in dogs with the CYP2C41 gene to those without.
Given the major role for CYP2D15 in M1 formation in dogs, it is likely that factors influencing CYP2D15 activity such as genetic polymorphisms or co-administered CYP2D15 inducers or inhibitors would influence circulating M1 concentrations. Various CYP2D15 genetic polymorphisms have been reported (Roussel et al., 1998; Paulson et al., 1999) although it is unclear whether they substantially impact CYP2D15 activity. We showed that quinidine is a relatively potent inhibitor of M1 formation by DLMs and CYP2D15 therefore we would predict This article has not been copyedited and formatted. The final version may differ from this version. 18 that co-administration of quinidine with tramadol would decrease its analgesic efficacy.
However, this drug is not commonly used in dogs. Other potential CYP2D inhibitors that are more likely to be coadministered with tramadol for treatment of pain in dogs such as buprenorphine, methadone, paroxetine, and fluoxetine should be evaluated for effects on M1
formation.
Another important finding was the marked species difference in formation of M1 and M2
by dog, human, and cat liver microsomes. Based on published data on tramadol and metabolite plasma concentrations in dogs, we had hypothesized that M1 formation should be lowest with DLMs. Although we did confirm lower M1 formation compared with cats, M1 formation by DLMs was higher than for human liver microsomes. Consequently, additional mechanisms are likely to account for low M1 concentrations in dog plasma. One possibility is competition for substrate availability for O-demethylation to M1 by more rapid N-demethylation to M2. In support of this, we did show a much higher capacity for DLMs to form M2 compared with human and cat liver microsomes suggesting CYP2B11 and/or CYP3A12 mediated tramadol Ndemethylation is much more efficient in dogs. Another possibility is more rapid clearance of M1 in dogs compared with cats and humans. M1 appears to be cleared largely via N-demethylation to M5, which is also a major circulating tramadol metabolite in dogs. Although M5 has weak µ opioid-receptor effects when administered directly into the brain, peripheral administration has no opioid effects suggesting it is unable to effectively cross the blood-brain barrier (Gillen et al., 2000) . Consequently, this pathway (M1 conversion to M5) could be an important determinant of M1-dependent opioid effects and so future studies are needed to evaluate this pathway including identification of the responsible CYPs.
This article has not been copyedited and formatted. The final version may differ from this version. formation is predicted to predominate over M1 formation in dog intestinal mucosa, which could be evaluated in future studies of dog intestinal microsome preparations.
Another interesting finding is that we observed non-Michaelis-Menten biphasic enzyme kinetics in Eadie-Hofstee plots of M1 and M2 formation by both DLMs and recombinant enzymes. Biphasic kinetics were reported previously in several other studies for tramadol metabolism by human liver microsomes (Paar et al., 1992; Subrahmanyam et al., 2001 ). This was attributed in one study to the contribution of multiple low and high affinity CYP isoforms to the measured activity (Subrahmanyam et al., 2001 ). However we also observed biphasic kinetics for individual recombinant CYPs, suggesting instead the presence of low and high affinity catalytic sites for tramadol within the same enzyme, although other causes cannot be excluded (Seibert and Tracy, 2014) .
There was some evidence for stereoselectivity in tramadol metabolism in that M1 was formed about 2 times more efficiently from (+)-tramadol than from (-)-tramadol by both DLMs and CYP2D15. This could be a reflection of differences in binding of (+)-tramadol versus (-)-tramadol to the CYP2D15 enzyme active site/s thereby influencing catalytic efficiency. Both (Paar et al., 1992) and rat (Liu et al., 2003) liver microsomes. Furthermore, higher M2 formation from (-)-tramadol compared with (+)-tramadol has been reported for human liver microsomes (Paar et al., 1992) . These species differences probably reflect differences in binding of (+)-tramadol and (-)-tramadol to the respective CYP active sites between species. The clinical implications of these differences in stereoselective metabolism of tramadol with regard to the analgesic effects of this drug remain to be determined.
In conclusion, the results of this study suggest that lower circulating concentrations of the tramadol M1 metabolite in dogs compared with humans and cats may be explained by more efficient formation of the tramadol M2 metabolite through a competing pathway. Additionally, multiple approaches identified CYP2D15 as the predominant CYP mediating formation of M1, while M2 was formed mainly by CYP2B11 and CYP3A12 in canine liver.
